

Targeted therapy is the **Best option**

for **ALK** positive **Lung Cancer**

Crizonix

Crizotinib INN 250 mg capsule

Better in targeting ALK

Crizotinib is superior than standard chemotherapy

In phase 3 open label trial comparing Crizotinib and chemotherapy in 347 patients with locally advanced or metastatic ALK- positive lung cancer.

Result:


Progression Free Survival (PFS)

Superiority of Crizotinib vs Standard chemotherapeutic agent



Response Rate

Superiority of Crizotinib vs Standard chemotherapeutic agent



Efficacy Ensured



Convenient twice daily dose

Better oral option for ALK-positive NSLC

Greater improvement in quality of life

